Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.27%
#2 aelf aelf +23.11%
#3 Bitway Bitway +14.16%
#4 Decred Decred +12.61%
#5 Pons Pons +9.42%
#6 TRIA TRIA +8.74%
#7 Wibx Wibx +8.12%
#8 AtomOne AtomOne +7.63%
#9 DexNet DexNet +7.55%
#10 Status Status +6.90%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc

FRLN
Classifica tra le azioni #30820
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in... Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.
Prezzo delle azioni
$6.48
Ultima sincronizzazione: 2024-02-29
Capitalizzazione di mercato
$15.41M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
GB
Scambia Freeline Therapeutics Holdings plc (FRLN)

Categoria

Healthcare
Ricavi di Freeline Therapeutics Holdings plc (FRLN)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Freeline Therapeutics Holdings plc, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Freeline Therapeutics Holdings plc da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE